46 results on '"Johansson, Jan-Ove"'
Search Results
2. Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease
3. Growth Hormone and Syndrome X
4. Psychological Well-Being in Growth Hormone Deficiency and Central Nervous Effects of Growth Hormone
5. Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study
6. Cerebrospinal Fluid Microglial Markers in Alzheimer’s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility
7. Diverse vasopressin V2 receptor functionality underlying partial congenital nephrogenic diabetes insipidus
8. Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women
9. Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study
10. Growth hormone and psychosocial and central nervous effects
11. Psychological Well-Being in Growth Hormone Deficiency and Central Nervous Effects of Growth Hormone
12. Identification of Adrenocorticotropin Receptor Messenger Ribonucleic Acid in the Human Pituitary and Its Loss of Expression in Pituitary Adenomas
13. Effects of Seven Years of GH-Replacement Therapy on Insulin Sensitivity in GH-Deficient Adults
14. Growth hormone (GH) replacement in GH-deficient adults: a crossover trial comparing the effect on metabolic control, well-being and compliance of three injections per week versus daily injections
15. A Novel Synonymous Variant in the AVP Gene Associated with Autosomal Dominant Familial Neurohypophyseal Diabetes Insipidus Causes Partial RNA Missplicing
16. Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults
17. A Novel Synonymous Variant in the AVP Gene Associated with Autosomal Dominant Familial Neurohypophyseal Diabetes Insipidus Causes Partial RNA Missplicing
18. Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer’s Disease
19. Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment
20. Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease
21. Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer’s Disease
22. A Novel Synonymous Variant in the <bold>AVP</bold> Gene Associated with Autosomal Dominant Familial Neurohypophyseal Diabetes Insipidus Causes Partial RNA Missplicing.
23. Growth Hormone and Syndrome X
24. Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease
25. Metabolic and central nervous effects of growth hormone in growthhormone-deficient adults
26. P1-129: Cerebrospinal fluid markers of microglial activation and neuroinflammation in Alzheimer's disease
27. Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population
28. Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases
29. P3-206: Convergence of chromogranin and amyloid metabolism in the brain
30. Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain
31. CHARACTERIZATION OF MUTANT V2 RECEPTORS ASSOCIATED WITH PARTIAL CONGENITAL NEPHROGENIC DIABETES INSIPIDUS
32. Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density
33. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease
34. Diurnal Variations in Twenty-Four-Hour Energy Expenditure During Growth Hormone Treatment of Adults with Pituitary Deficiency*
35. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults. II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity
36. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: 1. effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis
37. Long-term Treatment with Growth Hormone Decreases Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator in Growth Hormone-deficient Adults
38. Growth hormone-deficient adults are insulin-resistant
39. Consequences of Growth Hormone Deficiency in Adults and the Benefits and Risks of Recombinant Human Growth Hormone Treatment
40. Treatment of Growth Hormone-Deficient Adults with Recombinant Human Growth Hormone Increases the Concentration of Growth Hormone in the Cerebrospinal Fluid and Affects Neurotransmitters
41. Consequences of Growth Hormone Deficiency (GHD) in Adults and the Effects of Replacement Therapy with Recombinant Human Growth Hormone (rhGH)
42. Diverse vasopressin V2 receptor functionality underlying partial congenital nephrogenic diabetes insipidus.
43. Cerebrospinal fluid markers of microglial activation and neuroinflammation in Alzheimer's disease
44. Convergence of chromogranin and amyloid metabolism in the brain
45. Enzyme replacement in Anderson-Fabry disease.
46. Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.